%0 Journal Article
%T The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses.
%A Fisman D
%A Giglio N
%A Levin MJ
%A Nguyen VH
%A Pelton SI
%A Postma M
%A Ruiz-Aragón J
%A Urueña A
%A Mould-Quevedo JF
%J Hum Vaccin Immunother
%V 20
%N 1
%D 2024 Dec 31
%M 38835218
%F 4.526
%R 10.1080/21645515.2024.2351675
%X Seasonal influenza significantly affects both health and economic costs in children and adults. This narrative review summarizes published cost-effectiveness analyses (CEAs) of cell-based influenza vaccines in children and adults <65 years of age, critically assesses the assumptions and approaches used in these analyses, and considers the role of cell-based influenza vaccines for children and adults. CEAs from multiple countries demonstrated the cost-effectiveness of cell-based quadrivalent influenza vaccines (QIVc) compared with egg-based trivalent/quadrivalent influenza vaccines (TIVe/QIVe). CEA findings were consistent across models relying on different relative vaccine effectiveness (rVE) estimate inputs, with the rVE of QIVc versus QIVe ranging from 8.1% to 36.2% in favor of QIVc. Across multiple scenarios and types of analyses, QIVc was consistently cost-effective compared with QIVe, including in children and adults across different regions of the world.